Lotte Biologics announced on Thursday that it has signed a manufacturing deal with a biotech firm based in Asia to produce a clinical-stage antibody-drug conjugate candidate.
The deal represents the first major milestone in launching full-scale operations at the company’s ADC manufacturing facility, located at the Syracuse Bio Campus in the US state of New York, an expansion project that began in 2023.
Through the contract, Lotte Biologics is officially introducing its ADC contract development and manufacturing services, tailored to support clients across all stages, from clinical trials to commercial-scale production.
"With this contract as a starting point, we will ensure a stable supply of high-quality ADC therapeutics and solidify our position in the global market, not only as an antibody manufacturer, but also as a CDMO specializing in ADCs,” Lotte Biologics CEO James Park said. “We also plan to actively pursue partnerships to further strengthen our competitiveness in the ADC modality business."
Lotte Biologics will continue to seek new clients and expand its collaborative efforts, aiming to provide integrated, one-stop solutions for ADC development and production, the firm said.
Developed with an investment of around $100 million, Lotte Biologics’ ADC facility meets the current Good Manufacturing Practices of the US Food and Drug Administration and delivers comprehensive end-to-end manufacturing services.
The facility includes a fully integrated production and purification system, featuring a conjugation reactor capable of handling up to 1,000 liters. It also offers in-house quality control testing and advanced analytical characterization services.
Additionally, the site is outfitted with a single-use system that supports the entire workflow — from antibody preprocessing to the automated aseptic filling of drug substances — allowing for flexible and efficient service tailored to diverse client requirements.
hykim@heraldcorp.com
